Drugs / Hydrocortisone
Hydrocortisone
also known as
therapeutic hydrocortisone · Hydrocortisone Sodium Succinate · cortisol · hydrocortisone acetate · Solucortef · Cortef · Hydrocortisone hemisuccinate · Plenadren · +24 more
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Plenadren | — | 2011-11-03 | europa.eu ↗ |
| Approved | US (FDA) | HYDROCORTONE | — | 1951-12-21 | fda.gov ↗ |
Trials 213 · started per year
today
US approved 1951
EU approved 2011
1
2
1
2
2
5
4
4
5
8
8
17
12
8
5
14
4
6
11
14
5
13
12
10
7
8
4
8
6
7
195019511952195319541955195619571958195919601961196219631964196519661967196819691970197119721973197419751976197719781979198019811982198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027202820292030
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 013 trials | ||||||
| Phase 0 | NCT07612631 | Jun 2026 → Jun 2031 expected | alcohol-related disorders | Rajesh Narendran | Recruiting | No outcome recorded |
| Phase 0 | NCT06430580 | Sep 2024 → Sep 2026 expected | cannabis dependence | Florida State University | Recruiting | No outcome recorded |
| Phase 0 | NCT05919992 | May 2023 → Jul 2024 | glucocorticoid therapy, response to | Eleonora Seelig | Completed | No outcome recorded |
| Phase 0 | NCT05167084 | Feb 2022 → Jun 2023 | glucocorticoid therapy, response to | Eleonora Seelig | Completed | No outcome recorded |
| Phase 0 | NCT04896489 | May 2021 → Mar 2022 | alcohol-related disorders | Yale University | Completed | No outcome recorded |
| Phase 0 | NCT04148261 | Dec 2020 → Dec 2022 | depressive disorder | Stanford University | Withdrawn | No outcome recorded |
| Phase 0 | NCT04037605 | Feb 2020 → Jul 2022 overdue | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Active not recruiting | No outcome recorded |
| Phase 0 | NCT04435912 | Jul 2019 → Apr 2020 | — | University of Jordan | Completed | No outcome recorded |
| Phase 0 | NCT01422733 | Jun → Jul 2018 | obesity disorder, polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT01422707 | Jan → Jul 2018 | obesity disorder, polycystic ovary syndrome | University of Virginia | Withdrawn | No outcome recorded |
| Phase 0 | NCT03237689 | Nov 2017 → Sep 2023 | HIV infectious disease | Johns Hopkins University | Completed | No outcome recorded |
| Phase 0 | NCT02837432 | Jul 2016 → Dec 2019 | depressive disorder | Stanford University | Completed | No outcome recorded |
| Phase 0 | NCT03302416 | Jun 2016 → Jun 2019 | — | University of Pittsburgh | Completed | No outcome recorded |
| Phase 114 trials | ||||||
| Phase 1 | NCT04852458 | May 2021 → Nov 2022 | — | University of Michigan | Completed | No outcome recorded |
| Phase 1 | NCT03718234 | Jan 2019 → Feb 2023 | adrenal gland hyperfunction, congenital adrenal hyperplasia, disorder of sexual differentiation, hyperplasia +1 | University of Minnesota | Completed | No outcome recorded |
| Phase 1 | NCT03311932 | Apr → Jul 2018 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03343327 | Feb → Apr 2018 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03178214 | May → Jul 2017 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03142893 | May 2017 → Oct 2020 overdue | — | Peter y. Liu | Active not recruiting | No outcome recorded |
| Phase 1 | NCT02722200 | May 2016 → Jul 2017 | obesity disorder | Yale University | Completed | No outcome recorded |
| Phase 1 | NCT02671058 | Mar → May 2016 | — | Cristcot LLC | Completed | No outcome recorded |
| Phase 1 | NCT03670212 | Jan → Oct 2016 | — | Wayne State University | Completed | No outcome recorded |
| Phase 1 | NCT01960530 | Oct 2013 → Nov 2014 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT01265017 | Jul 2012 → Jun 2020 | type 1 diabetes mellitus | Sansum Diabetes Research Institute | Withdrawn | No outcome recorded |
| Phase 1 | NCT03051893 | Feb 2011 → Apr 2012 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT03019614 | Mar → Apr 2010 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT01055249 | Jan → Jun 2010 | — | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1/29 trials | ||||||
| Phase 1/2 | NCT05157360 | Sep 2021 → May 2023 | infectious disease with sepsis, necrotizing soft tissue infection | Ascension Health | Terminated | No outcome recorded |
| Phase 1/2 | NCT03649633 | Sep 2018 → Jan 2023 | infectious disease with sepsis | University of Athens | Terminated | No outcome recorded |
| Phase 1/2 | NCT03015246 | Dec 2016 → Jun 2020 | heroin dependence | Wayne State University | Completed | No outcome recorded |
| Phase 1/2 | NCT02790788 | Nov 2016 → May 2018 | cardiac arrest | University of Athens | Completed | No outcome recorded |
| Phase 1/2 | NCT02096510 | Mar 2014 → Dec 2016 | congenital adrenal hyperplasia | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 1/2 | NCT02922374 | Jan 2013 → Jun 2016 | colitis | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT00673270 | May → Oct 2008 | hypertensive disorder | Rennes University Hospital | Terminated | No outcome recorded |
| Phase 1/2 | NCT00676585 | Oct 2007 → Apr 2014 | cardiac arrest | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT00519818 | Aug 2007 → May 2009 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 239 trials | ||||||
| Phase 2 | NCT04231708 | Oct 2026 → Dec 2028 expected | substance-related disorder | Wayne State University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06381661 | May 2026 → Jun 2028 expected | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06895473 | Jun 2025 → Apr 2027 expected | hematopoietic and lymphoid system neoplasm | OHSU Knight Cancer Institute | Recruiting | No outcome recorded |
| Phase 2 | NCT04180969 | Apr 2023 | — | Wayne State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT05160506 | Mar 2022 → Jan 2027 expected | acute pancreatitis | Beth Israel Deaconess Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT05112354 | Dec 2019 → Jun 2021 | sudden sensorineural hearing loss | Assiut University | Completed | No outcome recorded |
| Phase 2 | NCT03710187 | Nov 2018 → Sep 2019 | infectious disease with sepsis | University of Tennessee Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03592693 | Sep 2018 → Jan 2023 | — | University of Athens | Terminated | No outcome recorded |
| Phase 2 | NCT03422159 | Feb 2018 → Jun 2019 | infectious disease with sepsis | Community Medical Center, Toms River, NJ | Completed | No outcome recorded |
| Phase 2 | NCT02465606 | Jul 2015 → May 2016 | atopic eczema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02689856 | May → Sep 2015 | hemorrhoid | Citius Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02339350 | Jan 2015 → Apr 2023 | acute lymphoblastic leukemia | The Korean Society of Pediatric Hematology Oncology | Unknown | No outcome recorded |
| Phase 2 | NCT02229136 | Sep 2014 → Nov 2022 | breast cancer, stomatitis | US Oncology Research | Completed | No outcome recorded |
| Phase 2 | NCT02043587 | Jan 2014 → Apr 2022 | acute lymphoblastic leukemia | University of California, San Diego | Terminated | No outcome recorded |
| Phase 2 | NCT01859312 | May 2013 → Dec 2016 | adrenal gland hyperfunction, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | National Institutes of Health Clinical Center (CC) | Completed | No outcome recorded |
| Phase 2 | NCT01860664 | May 2013 → May 2016 | conjunctivitis | Koffler Vision Group | Terminated | No outcome recorded |
| Phase 2 | NCT01735617 | Dec 2012 → Dec 2013 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 2 | NCT01718964 | Nov 2012 → Jul 2013 | opiate dependence | University of Basel | Completed | No outcome recorded |
| Phase 2 | NCT01451515 | May 2012 → May 2021 | lymphoblastic lymphoma | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01973855 | Jan 2012 → Mar 2015 | dengue disease, viral hemorrhagic fever | Guangzhou 8th People's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01460615 | Feb 2011 → Jan 2017 | pancreatitis | Tampere University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01104025 | Apr 2010 → Nov 2015 | hemophagocytic syndrome | Children's Hospital Medical Center, Cincinnati | Completed | No outcome recorded |
| Phase 2 | NCT01036594 | Dec 2009 → Dec 2012 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00980135 | Nov 2009 → May 2010 | atopic eczema | Bayer | Completed | No outcome recorded |
| Phase 2 | NCT00473083 | Jan 2009 → Dec 2012 | exanthem | British Columbia Cancer Agency | Completed | No outcome recorded |
| Phase 2 | NCT00805285 | Oct 2008 → Oct 2009 | ulcerative colitis | University of Maryland, Baltimore | Terminated | No outcome recorded |
| Phase 2 | NCT00704262 | May 2008 → Dec 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 2 | NCT00657306 | May → Dec 2008 | cirrhosis of liver | University of Turin, Italy | Unknown | No outcome recorded |
| Phase 2 | NCT00732277 | Apr 2008 → Apr 2012 | infectious disease with sepsis | University Hospital Southampton NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT00621985 | Apr 2008 → Jun 2009 | congenital adrenal hyperplasia | Boston Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00476190 | Apr 2007 → Sep 2013 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00317070 | Apr 2006 → Feb 2009 | interstitial cystitis | Nova Scotia Health Authority | Terminated | No outcome recorded |
| Phase 2 | NCT00332163 | Apr 2006 → Jan 2008 | colorectal cancer, exanthem, toxic dermatosis | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00167544 | Nov 2005 → Jan 2009 | bronchopulmonary dysplasia, encephalomalacia | Nationwide Children's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00097474 | Dec 2004 → Jan 2006 | circadian rhythm sleep disorder, jet lag type | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Completed | No outcome recorded |
| Phase 2 | NCT00309894 | Apr 2004 → Nov 2007 | prostate cancer | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00590018 | Feb 2003 → Dec 2009 | heart failure | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 2 | NCT00220454 | Dec 2002 → Mar 2005 | — | Seattle Institute for Biomedical and Clinical Research | Completed | No outcome recorded |
| Phase 2 | NCT00004669 | Jun 1996 → ? | bronchopulmonary dysplasia | National Center for Research Resources (NCRR) | Completed | No outcome recorded |
| Phase 2/39 trials | ||||||
| Phase 2/3 | NCT06496997 | Aug 2024 → Aug 2025 overdue | acute respiratory distress syndrome | Fayoum University | Recruiting | No outcome recorded |
| Phase 2/3 | NCT05534334 | May → Nov 2022 | pyogenic granuloma | Beni-Suef University | Unknown | No outcome recorded |
| Phase 2/3 | NCT03682393 | Jan 2020 → Dec 2022 | atrial fibrillation | Kuopio University Hospital | Withdrawn | No outcome recorded |
| Phase 2/3 | NCT03380507 | Mar 2018 → Oct 2019 | infectious disease with sepsis | Hamad Medical Corporation | Terminated | No outcome recorded |
| Phase 2/3 | NCT03389555 | Feb 2018 → Nov 2019 | infectious disease with sepsis, metabolic disease | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2/3 | NCT02552251 | Aug 2012 → Dec 2015 | classic congenital adrenal hyperplasia | University Hospital, Caen | Unknown | No outcome recorded |
| Phase 2/3 | NCT01063569 | Feb 2010 → Dec 2012 | primary adrenal insufficiency | Haukeland University Hospital | Completed | No outcome recorded |
| Phase 2/3 | NCT01047670 | May 2008 → ? | — | Unidade de Terapia Intensiva | Unknown | No outcome recorded |
| Phase 2/3 | NCT00563303 | Nov 2006 | — | Nantes University Hospital | Completed | No outcome recorded |
| Phase 352 trials | ||||||
| Phase 3 | NCT07332325 | Oct 2026 → Mar 2029 expected | infectious disease with sepsis, tuberculosis | University of Virginia | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07037043 | Apr 2025 → May 2028 expected | — | Centre Hospitalier Universitaire, Amiens | Recruiting | No outcome recorded |
| Phase 3 | NCT05816226 | Jun 2023 → Jan 2026 overdue | temporomandibular joint disorder | University of the Pacific | Recruiting | No outcome recorded |
| Phase 3 | NCT05668455 | May 2023 → Dec 2025 overdue | — | Agnes | Recruiting | No outcome recorded |
| Phase 3 | NCT05299554 | Apr 2022 → Jan 2026 | congenital adrenal hyperplasia | Immedica Pharma AB | Completed | No outcome recorded |
| Phase 3 | NCT04404400 | Feb 2022 → Feb 2026 overdue | adrenocortical insufficiency | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04821583 | Jun 2021 → Sep 2022 | multiple symmetric lipomatosis | Erasmus Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT04591990 | May 2021 → Dec 2025 overdue | post-cardiac arrest syndrome | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT04469686 | Dec 2020 → Jul 2024 | proctitis | Cristcot LLC | Completed | No outcome recorded |
| Phase 3 | NCT04359511 | Jul 2020 | COVID-19 | University Hospital, Tours | Withdrawn | No outcome recorded |
| Phase 3 | NCT04348305 | Apr → Sep 2020 | COVID-19 | Scandinavian Critical Care Trials Group | Completed | No outcome recorded |
| Phase 3 | NCT04134403 | Dec 2019 → Nov 2020 | infectious disease with sepsis | Baqiyatallah Medical Sciences University | Unknown | No outcome recorded |
| Phase 3 | NCT03936517 | Jul 2019 → Feb 2025 | adrenocortical insufficiency | Imperial College London | Unknown | No outcome recorded |
| Phase 3 | NCT03773822 | Apr 2019 → Apr 2023 | cardiogenic shock | CMC Ambroise Paré | Completed | No outcome recorded |
| Phase 3 | NCT03872011 | Feb 2019 → Sep 2021 | infectious disease with sepsis | Northern Jiangsu People's Hospital | Completed | No outcome recorded |
| Phase 3 | NCT03509350 | Aug 2018 → Aug 2019 | infectious disease with sepsis | Emory University | Completed | No outcome recorded |
| Phase 3 | NCT03062280 | Aug 2016 → Jul 2022 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 3 | NCT02735707 | Apr 2016 → Feb 2026 overdue | pneumonia | UMC Utrecht | Recruiting | No outcome recorded |
| Phase 3 | NCT02733367 | Mar 2016 → Aug 2018 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 3 | NCT02716818 | Feb 2016 → Jul 2018 | congenital adrenal hyperplasia | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 3 | NCT02517489 | Oct 2015 → Jul 2020 | — | University Hospital, Tours | Completed | No outcome recorded |
| Phase 3 | NCT02720952 | Mar 2015 → Jul 2016 | adrenocortical insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 3 | NCT00980876 | Apr 2012 → Jan 2015 | acute otitis externa | Farmoquimica S.A. | Completed | No outcome recorded |
| Phase 3 | NCT01574612 | Mar → Dec 2012 | herpes labialis | Meda Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02883049 | Feb 2012 → Dec 2022 | B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like, central nervous system leukemia, testicular leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT01996748 | Feb → Mar 2012 | atopic eczema | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT06260462 | Jan 2012 → Sep 2022 | adrenocortical insufficiency | University of Palermo | Completed | No outcome recorded |
| Phase 3 | NCT02266589 | Nov 2011 → Oct 2013 | infectious disease with sepsis | Nanjing PLA General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01353313 | Aug 2011 → Sep 2020 | bronchopulmonary dysplasia, fetal growth restriction, pulmonary immaturity | NICHD Neonatal Research Network | Completed | No outcome recorded |
| Phase 3 | NCT01313221 | Apr 2011 → Dec 2012 | psoriasis | Amgen | Completed | No outcome recorded |
| Phase 3 | NCT01093261 | Aug 2010 → Nov 2012 | adrenocortical insufficiency, pneumonia, traumatic brain injury | Nantes University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01014364 | Mar 2010 → Jun 2011 | influenza, viral pneumonia | University of Versailles | Terminated | No outcome recorded |
| Phase 3 | NCT02114710 | May 2009 → Oct 2012 | — | Nanjing PLA General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00670254 | Jan 2009 → Aug 2013 | infectious disease with sepsis | Charite University, Berlin, Germany | Completed | No outcome recorded |
| Phase 3 | NCT00862381 | Oct 2008 → Jul 2010 | — | University Hospital, Grenoble | Completed | No outcome recorded |
| Phase 3 | NCT00729794 | Sep 2008 → Nov 2010 | cardiac arrest | University of Athens | Completed | No outcome recorded |
| Phase 3 | NCT00691002 | May 2008 → Jan 2010 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00623740 | Apr 2008 → Jan 2016 | bronchopulmonary dysplasia | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT00640822 | Feb 2008 → Jun 2009 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00591006 | Jan 2008 → Jul 2009 | — | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 3 | NCT00735761 | Dec 2006 → Sep 2007 | herpes labialis | Medivir | Completed | No outcome recorded |
| Phase 3 | NCT00705822 | Aug 2006 → Jul 2009 | prostate cancer | Sanofi | Terminated | No outcome recorded |
| Phase 3 | NCT00361881 | Jul 2006 → Aug 2007 | herpes labialis | Medivir | Completed | No outcome recorded |
| Phase 3 | NCT00358748 | Jul 2005 → May 2010 | — | University of British Columbia | Completed | No outcome recorded |
| Phase 3 | NCT00027859 | Oct 2003 → Dec 2004 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT01453686 | Aug 2002 → Aug 2003 | alopecia areata | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT00147004 | Mar 2002 → Nov 2005 | — | Hadassah Medical Organization | Completed | No outcome recorded |
| Phase 3 | NCT00019409 | Oct 1999 → Jul 2001 | leukemia | National Institutes of Health Clinical Center (CC) | Withdrawn | No outcome recorded |
| Phase 3 | NCT00003593 | Jun 1999 → Mar 2007 | leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00003436 | Jul 1998 → Dec 2005 | leukemia, myelodysplastic syndrome | Medical Research Council | Completed | No outcome recorded |
| Phase 3 | NCT00002744 | May 1996 → Mar 2007 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00001521 | Jun 1995 → Apr 2024 | congenital adrenal hyperplasia | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
| Phase 444 trials | ||||||
| Phase 4 | NCT07558811 | Apr → Dec 2026 expected | primary aldosteronism | Ruijin Hospital | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07383103 | Mar 2026 → Dec 2028 expected | infectious disease with sepsis | Northern Jiangsu People's Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07695337 | Jan → Jul 2026 | infectious disease with sepsis | Benha University | Completed | No outcome recorded |
| Phase 4 | NCT07124650 | Sep 2025 → Dec 2026 expected | — | Saint Petersburg State University, Russia | Recruiting | No outcome recorded |
| Phase 4 | NCT07262957 | Sep 2025 → Sep 2027 expected | ampulla of vater adenocarcinoma, cholangiocarcinoma, cystic neoplasm, neuroendocrine neoplasm +3 | Academic Medical Center - University of Amsterdam | Recruiting | No outcome recorded |
| Phase 4 | NCT07248761 | Feb 2025 → Jun 2026 overdue | hyperglycemia, neonatal sepsis, patent ductus arteriosus, perinatal asphyxia +4 | Coordinación de Investigación en Salud, Mexico | Active not recruiting | No outcome recorded |
| Phase 4 | NCT06679816 | Dec 2024 → Dec 2025 overdue | pituitary gland adenoma | Beijing Tiantan Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT06435481 | Sep 2024 → Sep 2025 overdue | adrenocortical insufficiency | Hospital Universitari Vall d'Hebron Research Institute | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06018727 | Jul 2024 → Jul 2025 | borderline personality disorder | University of North Carolina, Chapel Hill | Withdrawn | No outcome recorded |
| Phase 4 | NCT06637384 | Mar → Apr 2024 | diabetes mellitus | Rimsha Rasheed | Completed | No outcome recorded |
| Phase 4 | NCT05436535 | Nov 2022 → Apr 2025 | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 4 | NCT05658692 | Oct 2022 → Oct 2023 | acute respiratory distress syndrome | Second Affiliated Hospital, School of Medicine, Zhejiang University | Unknown | No outcome recorded |
| Phase 4 | NCT05350020 | Mar 2022 → Mar 2023 | primary adrenal insufficiency | The London Clinic | Unknown | No outcome recorded |
| Phase 4 | NCT05159284 | Nov 2021 → Dec 2024 | dry eye syndrome | Laboratorios Thea, Spain | Unknown | No outcome recorded |
| Phase 4 | NCT05457296 | Jan → Apr 2021 | secondary adrenal insufficiency | University Tunis El Manar | Completed | No outcome recorded |
| Phase 4 | NCT04536662 | Oct 2020 → Sep 2022 | congenital adrenal hyperplasia | Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04039815 | Dec 2019 → Dec 2020 | infectious disease with sepsis | Far Eastern Memorial Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03896659 | Oct 2019 → Sep 2024 | major depressive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT03845608 | Mar → Oct 2019 | — | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03800264 | May → Nov 2018 | atrial fibrillation | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03907865 | Mar → Nov 2018 | dry eye syndrome | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT03335124 | Sep 2017 → Dec 2018 | infectious disease with sepsis | University Medical Centre Ljubljana | Terminated | No outcome recorded |
| Phase 4 | NCT02282150 | Oct 2016 → Nov 2017 | secondary adrenal insufficiency | Ulla Feldt-Rasmussen | Unknown | No outcome recorded |
| Phase 4 | NCT03760835 | Aug 2016 → Dec 2026 expected | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Federico II University | Recruiting | No outcome recorded |
| Phase 4 | NCT02775227 | May 2016 → Jan 2019 overdue | pancreatic neoplasm | Helsinki University Central Hospital | Active not recruiting | No outcome recorded |
| Phase 4 | NCT02372110 | Mar → Nov 2015 | anxiety | University of Texas at Austin | Completed | No outcome recorded |
| Phase 4 | NCT02266264 | Oct 2014 → May 2017 | hyperglycemia | Srinakharinwirot University | Completed | No outcome recorded |
| Phase 4 | NCT02044159 | Jul 2014 → Apr 2016 | — | Children's Hospital of Eastern Ontario | Completed | No outcome recorded |
| Phase 4 | NCT02056418 | Jan 2014 → Jan 2016 | Crohn disease | Jinling Hospital, China | Unknown | No outcome recorded |
| Phase 4 | NCT01070225 | Mar → Aug 2010 | asthma | University of Dundee | Completed | No outcome recorded |
| Phase 4 | NCT00933023 | Aug → Sep 2009 | phimosis | Chelsea and Westminster NHS Foundation Trust | Withdrawn | No outcome recorded |
| Phase 4 | NCT00706173 | Aug 2009 → Sep 2011 | post-traumatic stress disorder | University of California, San Diego | Withdrawn | No outcome recorded |
| Phase 4 | NCT01399268 | Feb 2009 → Aug 2010 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT00674570 | Jan 2009 → Jun 2015 | post-traumatic stress disorder | VA Office of Research and Development | Completed | No outcome recorded |
| Phase 4 | NCT01769339 | Jan → Jun 2009 | vulvovaginal candidiasis | Janssen Pharmaceutica | Completed | No outcome recorded |
| Phase 4 | NCT00709839 | Jun → Oct 2008 | — | Medical University of Vienna | Completed | No outcome recorded |
| Phase 4 | NCT01150409 | May 2008 → Aug 2010 | infectious disease with sepsis | The Cleveland Clinic | Terminated | No outcome recorded |
| Phase 4 | NCT02768740 | Apr 2008 → May 2010 | infectious disease with sepsis | Association Niçoise de Réanimation Médicale | Completed | No outcome recorded |
| Phase 4 | NCT00415701 | Nov 2006 → Dec 2009 | coronary artery disorder, mitral valve insufficiency | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 4 | NCT00149123 | Apr 2005 → Oct 2010 | — | Hospices Civils de Lyon | Completed | No outcome recorded |
| Phase 4 | NCT00270777 | Mar 2005 → Apr 2008 | snakebite envenomation | University of Kelaniya | Completed | No outcome recorded |
| Phase 4 | NCT00853008 | Jan 2003 → Nov 2012 | acute lymphoblastic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT03558971 | Jan 2000 → Dec 2016 | rheumatic disorder | Helen Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00526305 | Jan 2000 → Apr 2005 | acute lymphoblastic leukemia | PETHEMA Foundation | Completed | No outcome recorded |
| Phase not applicable33 trials | ||||||
| — | NCT07313670 | Jul → Dec 2025 | infectious disease with sepsis | Muhammad Aamir Latif | Completed | No outcome recorded |
| — | NCT06556277 | Sep 2024 → Feb 2026 | overnutrition | Eleonora Seelig | Completed | No outcome recorded |
| — | NCT06217939 | Jun 2024 → Jun 2026 overdue | infectious disease with sepsis | Siriraj Hospital | Recruiting | No outcome recorded |
| — | NCT04597762 | Aug 2020 → Mar 2021 | dry eye syndrome | Hospital Hietzing | Completed | No outcome recorded |
| — | NCT04465539 | Jul 2020 → Feb 2024 | — | Tanta University | Completed | No outcome recorded |
| — | NCT04280497 | Apr 2020 → Dec 2025 overdue | infectious disease with sepsis | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| — | NCT04160676 | Dec 2019 → Jul 2021 | infectious disease with sepsis | Tanta University | Completed | No outcome recorded |
| — | NCT04536129 | Nov 2019 → Mar 2020 | eye adnexa disorder, glaucoma | University of Molise | Completed | No outcome recorded |
| — | NCT03748537 | Jan 2017 → Dec 2019 | infectious disease with sepsis | Chiang Mai University | Completed | No outcome recorded |
| — | NCT02580240 | Sep 2015 → Sep 2016 | infectious disease with sepsis | Northern Jiangsu People's Hospital | Completed | No outcome recorded |
| — | NCT02552654 | Sep → Nov 2015 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT02691858 | Apr 2015 → Jun 2025 overdue | intussusception | Cairo University | Recruiting | No outcome recorded |
| — | NCT02402114 | Feb 2015 → Feb 2016 | post-traumatic stress disorder | Albert Einstein Healthcare Network | Withdrawn | No outcome recorded |
| — | NCT02360046 | Jan 2015 → Dec 2016 | hypopituitarism | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| — | NCT00442494 | Oct 2012 | atrial fibrillation | Kuopio University Hospital | Terminated | No outcome recorded |
| — | NCT02417987 | May 2012 → Aug 2014 | disease of the tendon | Bispebjerg Hospital | Completed | No outcome recorded |
| — | NCT01595386 | Apr 2012 → Nov 2013 | congenital heart disease | University of Alabama at Birmingham | Completed | No outcome recorded |
| — | NCT01108133 | Oct 2010 → Mar 2013 | post-traumatic stress disorder | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| — | NCT01156480 | Sep 2009 → Nov 2012 | necrotizing enterocolitis | Endeavor Health | Terminated | No outcome recorded |
| — | NCT00855270 | Apr 2009 → Sep 2016 | post-traumatic stress disorder | Sheba Medical Center | Unknown | No outcome recorded |
| — | NCT01108146 | Oct 2008 → Oct 2012 | post-traumatic stress disorder | Central Institute of Mental Health, Mannheim | Completed | No outcome recorded |
| — | NCT00559481 | Oct 2007 → Sep 2008 | prostate cancer | Roswell Park Cancer Institute | Withdrawn | No outcome recorded |
| — | NCT00362661 | Jun 2007 → Dec 2009 | post-traumatic stress disorder | University of Zurich | Terminated | No outcome recorded |
| — | NCT00451750 | May 2007 → Sep 2009 | phobic disorder | University of Zurich | Completed | No outcome recorded |
| — | NCT00759005 | Mar 2007 → Jun 2008 | heroin dependence | National Institute on Drug Dependence, China | Completed | No outcome recorded |
| — | NCT00529841 | Jan 2007 → Sep 2008 | congenital adrenal hyperplasia | Baylor College of Medicine | Completed | No outcome recorded |
| — | NCT00396344 | Oct 2006 → Nov 2007 | infectious disease with sepsis | Dartmouth-Hitchcock Medical Center | Completed | No outcome recorded |
| — | NCT00451230 | Jun 2005 | cocaine dependence | National Institute on Drug Abuse (NIDA) | Completed | No outcome recorded |
| — | NCT00096135 | Nov 2004 → Sep 2013 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| — | NCT00172354 | Oct 2004 → May 2006 | cardiac arrest | National Taiwan University Hospital | Completed | No outcome recorded |
| — | NCT00049569 | Jan 2003 → Mar 2006 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| — | NCT00186264 | Aug 2002 → Apr 2006 | major depressive disorder | Stanford University | Completed | No outcome recorded |
| — | NCT00442390 | Jan 2002 → Jan 2003 | primary adrenal insufficiency | University of Aarhus | Completed | No outcome recorded |
Also used as a comparator or background therapy in 259 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 06 trials | ||||||
| Phase 0 | NCT07059975 Background | Oct 2025 → Oct 2028 expected | childhood acute myeloid leukemia | Joanna Yi | Recruiting | No outcome recorded |
| Phase 0 | NCT06942039 Background | Sep 2025 → Dec 2030 expected | atypical teratoid rhabdoid tumor, childhood medulloblastoma, embryonal tumor with multilayered rosettes, ependymoblastoma +5 | C17 Council | Recruiting | No outcome recorded |
| Phase 0 | NCT05674253 Comparator | Dec 2022 → Jun 2023 | atrial fibrillation | Ain Shams University | Unknown | No outcome recorded |
| Phase 0 | NCT05008146 Background | Dec 2020 → Sep 2028 expected | substance-related disorder | Rajesh Narendran | Recruiting | No outcome recorded |
| Phase 0 | NCT02256865 Comparator | Oct 2014 → Nov 2017 | — | Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center | Completed | No outcome recorded |
| Phase 0 | NCT00236925 Comparator | May 2003 → May 2007 | fibromyalgia | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 127 trials | ||||||
| Phase 1 | NCT07498465 Background | Sep 2026 → Nov 2028 | childhood acute lymphoblastic leukemia, childhood acute myeloid leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Withdrawn | No outcome recorded |
| Phase 1 | NCT06504160 Background | May 2025 → Dec 2026 expected | atopic eczema | National Institute of Allergy and Infectious Diseases (NIAID) | Recruiting | No outcome recorded |
| Phase 1 | NCT06247787 Background | Feb 2025 → Mar 2028 expected | childhood acute myeloid leukemia, childhood myelodysplastic syndrome, juvenile myelomonocytic leukemia | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 1 | NCT06177067 Background | Apr 2024 → Oct 2026 expected | acute leukemia of ambiguous lineage | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 1 | NCT06136598 Background | Jan 2024 → Mar 2026 | castration-resistant prostate carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT06104449 Background | Nov 2023 → Feb 2026 | castration-resistant prostate carcinoma | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT05292664 Background | Mar 2023 → Jul 2028 expected | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, lymphoblastic lymphoma, myelodysplastic syndrome +1 | Andrew E. Place, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT05476770 Background | Nov 2022 → Nov 2025 overdue | B-cell non-Hodgkin lymphoma, CD4+/CD56+ hematodermic neoplasm, Hodgkins lymphoma, acute undifferentiated leukemia +3 | Therapeutic Advances in Childhood Leukemia Consortium | Recruiting | No outcome recorded |
| Phase 1 | NCT04898894 Background | Nov 2021 → Jul 2023 overdue | acute leukemia of ambiguous lineage | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04615962 Comparator | Jan 2021 → Jan 2022 | atopic eczema | Seanergy Dermatology Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT03813147 Background | May 2019 → Sep 2021 | acute myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03792256 Background | Apr 2019 → Jun 2021 | T lymphoblastic leukemia/lymphoma, T-cell acute lymphoblastic leukemia, lymphoblastic lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1 | NCT03349281 Background | Mar 2019 → Aug 2021 | acute lymphoblastic leukemia | University of Miami | Completed | No outcome recorded |
| Phase 1 | NCT03515200 Background | Apr 2018 → Jul 2020 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT03194932 Background | Jul 2017 → Oct 2020 | acute myeloid leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02676323 Background | May 2016 → Apr 2018 | acute myeloid leukemia, myelodysplastic syndrome | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT01614197 Background | Jul 2015 → Dec 2019 | childhood acute lymphoblastic leukemia, lymphoblastic lymphoma, peripheral T-cell lymphoma, not otherwise specified | Therapeutic Advances in Childhood Leukemia Consortium | Completed | No outcome recorded |
| Phase 1 | NCT02270788 Background | Apr 2015 → Oct 2016 | acute myeloid leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02303821 Background | Feb 2015 → Jun 2024 | acute lymphoblastic leukemia | Amgen | Completed | No outcome recorded |
| Phase 1 | NCT02408068 Comparator | Jan → Mar 2015 | — | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT02212561 Background | Aug 2014 → Dec 2015 | acute lymphoblastic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 1 | NCT02777268 Comparator | Jul → Sep 2013 | — | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 1 | NCT01301677 Comparator | Jan → Jun 2011 | — | X-pert Med GmbH | Completed | No outcome recorded |
| Phase 1 | NCT01186328 Background | Aug 2010 → Jan 2012 | T-cell acute lymphoblastic leukemia, childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded |
| Phase 1 | NCT01064986 Comparator | Feb 2010 → Dec 2012 | infectious disease | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 1 | NCT00874393 Comparator | Jul 2009 → Dec 2010 | fetal growth restriction, hypotensive disorder | NICHD Neonatal Research Network | Completed | No outcome recorded |
| Phase 1 | NCT00928200 Background | Apr 2009 → Jun 2010 | acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Terminated | No outcome recorded |
| Phase 1/223 trials | ||||||
| Phase 1/2 | NCT07175415 Background | Oct 2026 → Oct 2031 expected | T lymphoblastic leukemia/lymphoma, acute lymphoblastic leukemia | Princess Maxima Center for Pediatric Oncology | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07387926 Background | Jul 2026 → Sep 2033 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05751044 Background | Oct 2025 → Feb 2032 expected | T lymphoblastic leukemia/lymphoma, acute lymphoblastic leukemia | Princess Maxima Center for Pediatric Oncology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05745714 Background | Oct 2025 → Feb 2032 expected | T-lymphoblastic lymphoma, acute lymphoblastic leukemia | Princess Maxima Center for Pediatric Oncology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05658640 Background | Nov 2023 → Apr 2029 expected | T-lymphoblastic lymphoma, acute lymphoblastic leukemia | Princess Maxima Center for Pediatric Oncology | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05740449 Background | Oct 2023 → Oct 2029 | T-lymphoblastic lymphoma, acute lymphoblastic leukemia | Princess Maxima Center for Pediatric Oncology | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05320380 Background | Aug → Sep 2023 | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05192889 Background | Aug 2022 → Jun 2024 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04501614 Background | Feb 2021 → Dec 2023 | B-lymphoblastic leukemia/lymphoma, BCR-ABL1–like, childhood acute lymphoblastic leukemia, mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2) | Takeda | Terminated | No outcome recorded |
| Phase 1/2 | NCT04029688 Background | Jan 2020 → May 2024 | acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma | Hoffmann-La Roche | Terminated | No outcome recorded |
| Phase 1/2 | NCT03817320 Background | Feb 2019 → Dec 2023 overdue | childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03793478 Background | Aug 2018 → May 2027 expected | acute myeloid leukemia | Daiichi Sankyo | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03358082 Comparator | Oct 2017 → Dec 2018 | vitiligo | Sohag University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02553460 Background | Jan 2016 → May 2022 overdue | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02481310 Background | Oct 2015 → Sep 2020 | Burkitt lymphoma, plasmablastic lymphoma | Northwestern University | Unknown | No outcome recorded |
| Phase 1/2 | NCT02301052 Comparator | Sep → Nov 2014 | hemorrhoid | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| Phase 1/2 | NCT02756546 Comparator | Sep 2014 → Sep 2015 | systemic lupus erythematosus | Cairo University | Completed | No outcome recorded |
| Phase 1/2 | NCT00953576 Background | Sep 2009 → Apr 2013 | prostate cancer | Dana-Farber Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00354107 Background | Jan 2007 → Jan 2010 | anaplastic large cell lymphoma | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 1/2 | NCT00536991 Background | Oct 2006 → Oct 2016 | prostate adenocarcinoma | Roswell Park Cancer Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT00440726 Background | Aug 2006 → Feb 2011 | childhood acute lymphoblastic leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Completed | No outcome recorded |
| Phase 1/2 | NCT00098839 Background | Feb 2005 → Apr 2011 | childhood acute lymphoblastic leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 1/2 | NCT00005802 Background | Jun 1999 → Mar 2005 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 277 trials | ||||||
| Phase 2 | NCT07686107 Background | Aug 2026 → Dec 2029 expected | acute myeloid leukemia | Therapeutic Advances in Childhood Leukemia Consortium | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06446245 Background | Aug 2025 → Nov 2027 expected | meningeal tuberculosis | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 2 | NCT06979596 Background | Aug 2025 → Nov 2027 expected | cancer | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 2 | NCT06317662 Background | Jun 2025 → Dec 2028 expected | B-cell acute lymphoblastic leukemia, acute leukemia of ambiguous lineage | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT06390319 Background | Dec 2024 → Dec 2027 expected | T-cell acute lymphoblastic leukemia, T-cell non-Hodgkin lymphoma, mixed phenotype acute leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT05761171 Background | Jan 2024 → Dec 2027 expected | acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05818826 Comparator | Jul 2023 → Apr 2025 | coinfection, hyperglycemia, infectious disease with sepsis | Mahidol University | Unknown | No outcome recorded |
| Phase 2 | NCT04181515 Comparator | Apr 2023 | opiate dependence | Wayne State University | Withdrawn | No outcome recorded |
| Phase 2 | NCT05656248 Background | Jan 2023 → Aug 2025 overdue | myeloid neoplasm | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03548246 Background | Jan 2023 → Jan 2026 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | University of Texas Southwestern Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05607901 Comparator | Oct 2022 → Nov 2023 | skin disorder | Tanta University | Completed | No outcome recorded |
| Phase 2 | NCT04924166 Comparator | Jan 2022 → Jul 2025 | acute stress disorder, post-traumatic stress disorder | Rachel Yehuda | Completed | No outcome recorded |
| Phase 2 | NCT04921189 Comparator | Dec 2021 → Dec 2024 | cardiac arrest, post-cardiac arrest syndrome | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT05222152 Comparator | Nov 2021 → Oct 2023 | primary adrenal insufficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 2 | NCT04546399 Background | Dec 2020 → Jun 2028 expected | Down syndrome, acute lymphoblastic leukemia | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 2 | NCT05276323 Comparator | Oct 2020 → Feb 2021 | atopic eczema | Soroka University Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT03913559 Background | May 2019 → Sep 2025 | acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT03335774 Comparator | Feb 2019 → Mar 2021 | internal hemorrhoid | Nivagen Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03333278 Background | May 2018 → Jul 2019 | infectious disease with sepsis | Australian and New Zealand Intensive Care Research Centre | Completed | No outcome recorded |
| Phase 2 | NCT03164057 Background | Jun 2017 → Sep 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | St. Jude Children's Research Hospital | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03286634 Background | Apr 2017 → Mar 2028 expected | Down syndrome, acute lymphoblastic leukemia, childhood malignant neoplasm | National Hospital Organization Nagoya Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT02828358 Background | Apr 2017 → Sep 2020 | B-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT03261336 Background | Jan 2017 → Feb 2018 | castration-resistant prostate carcinoma | Donald Trump, MD | Terminated | No outcome recorded |
| Phase 2 | NCT02518750 Background | Nov 2016 → Mar 2018 | T-cell leukemia, acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02776605 Background | Jun 2016 → Aug 2020 | — | PETHEMA Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT03071276 Background | Jan 2016 → Apr 2019 | acute myeloid leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02535806 Background | Jul 2015 → May 2017 | acute lymphoblastic leukemia, lymphoblastic lymphoma | Children's Mercy Hospital Kansas City | Terminated | No outcome recorded |
| Phase 2 | NCT02230930 Comparator | Jun 2015 → Dec 2018 | Parkinson disease | University Medical Center Groningen | Terminated | No outcome recorded |
| Phase 2 | NCT02433483 Background | May 2015 → May 2017 | acute myeloid leukemia, myelodysplastic syndrome | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02340234 Background | May 2015 → Apr 2016 | atopic eczema | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 2 | NCT02419755 Background | Apr 2015 → Dec 2016 | acute lymphoblastic leukemia, mixed phenotype acute leukemia | St. Jude Children's Research Hospital | Terminated | No outcome recorded |
| Phase 2 | NCT02090309 Comparator | Mar 2014 → Dec 2015 | nervous system injury | Soroka University Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT05049473 Background | Jan 2014 → Jan 2024 | Burkitt lymphoma | PETHEMA Foundation | Unknown | No outcome recorded |
| Phase 2 | NCT01913158 Comparator | Oct 2013 → Mar 2014 | internal hemorrhoid | G & W Laboratories Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01847690 Comparator | Jun 2013 → Jan 2014 | primary adrenal insufficiency | Haukeland University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01700946 Comparator | Apr 2013 → Jul 2021 | B-cell childhood acute lymphoblastic leukemia | St. Jude Children's Research Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01771328 Comparator | Feb 2013 → Jan 2017 | congenital adrenal hyperplasia | Haukeland University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01828515 Background | Dec 2012 → Apr 2014 | cognitive disorder | University of Texas Southwestern Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT01867294 Comparator | Aug 2012 → May 2014 | metastatic malignant neoplasm, toxic dermatosis | Academic and Community Cancer Research United | Completed | No outcome recorded |
| Phase 2 | NCT01450930 Comparator | Nov 2011 → Jul 2012 | primary adrenal insufficiency | Bruno Allolio | Completed | No outcome recorded |
| Phase 2 | NCT01574014 Comparator | Jul 2009 → Mar 2012 | phobic disorder | Insel Gruppe AG, University Hospital Bern | Terminated | No outcome recorded |
| Phase 2 | NCT00859781 Background | Jun 2009 → Feb 2022 overdue | prostate cancer | Weill Medical College of Cornell University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT00899847 Background | May 2009 → Apr 2014 | plasma cell myeloma | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00895310 Background | May 2009 → Dec 2014 | prostate cancer | University of California, Davis | Completed | No outcome recorded |
| Phase 2 | NCT00873093 Background | Mar 2009 → Sep 2014 | B-cell adult acute lymphocytic leukemia, B-cell childhood acute lymphoblastic leukemia, T-cell adult acute lymphocytic leukemia, T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01005758 Background | Jan 2009 → Jan 2013 | leukemia | Ohio State University Comprehensive Cancer Center | Unknown | No outcome recorded |
| Phase 2 | NCT00623766 Background | Jul 2008 → Sep 2009 | melanoma | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT00610142 Comparator | Dec 2007 → Aug 2008 | atopic eczema | Technical University Dresden | Completed | No outcome recorded |
| Phase 2 | NCT00507832 Comparator | Apr 2007 → Jun 2009 | prurigo nodularis | University Hospital Muenster | Completed | No outcome recorded |
| Phase 2 | NCT00482053 Background | Oct 2006 → May 2010 | diffuse large B-cell lymphoma | Stanford University | Terminated | No outcome recorded |
| Phase 2 | NCT00460031 Background | Sep 2006 → Aug 2010 | prostate cancer | Case Comprehensive Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT00392834 Background | Sep 2006 → Jul 2011 | lymphoma | AIDS Malignancy Consortium | Completed | No outcome recorded |
| Phase 2 | NCT00298155 Comparator | Jul 2006 → Jun 2010 | cancer, prostate neoplasm | University of Washington | Completed | No outcome recorded |
| Phase 2 | NCT00618501 Background | Oct 2005 → Dec 2008 | leukemia | Asan Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00133991 Background | Jul 2005 → Aug 2011 | leukemia, lymphoma | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Completed | No outcome recorded |
| Phase 2 | NCT01423864 Comparator | Jun 2005 → Jun 2009 | acute respiratory distress syndrome, multiple organ dysfunction syndrome | National Taiwan University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT00186628 Background | Jun 2005 → Nov 2010 | mantle cell lymphoma, mast cell leukemia | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00673127 Background | Feb 2005 → Feb 2012 | prostate cancer | Beth Israel Deaconess Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT00057811 Background | Jun 2004 → Oct 2009 | Burkitt lymphoma, childhood acute lymphoblastic leukemia, diffuse large B-cell lymphoma, large B-cell lymphoma +1 | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00181597 Background | Mar 2004 → Jan 2006 | prostate adenocarcinoma | Genzyme, a Sanofi Company | Completed | No outcome recorded |
| Phase 2 | NCT00801957 Comparator | Mar 2003 → Nov 2004 | atopic eczema | Astellas Pharma Inc | Completed | No outcome recorded |
| Phase 2 | NCT00084838 Background | Feb 2003 → Feb 2008 | central nervous system cancer | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00131053 Background | Sep 2002 → May 2011 | acute lymphoblastic leukemia | Japan Adult Leukemia Study Group | Unknown | No outcome recorded |
| Phase 2 | NCT00136435 Background | Jun 2002 → Nov 2008 | acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00176462 Background | Feb 2001 → Sep 2008 | acute lymphoblastic leukemia | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT00185692 Background | Aug 2000 → Dec 2010 | B-cell chronic lymphocytic leukemia, Hodgkins lymphoma, cancer, graft versus host disease +1 | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00006371 Comparator | May 2000 → Dec 2001 | prostate cancer | H. Lee Moffitt Cancer Center and Research Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00002805 Background | Aug 1997 → May 2001 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002970 Background | Jun 1997 → Jan 2005 | T-cell childhood acute lymphocytic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00002921 Background | Mar 1997 → Jan 2004 | adrenal cortex carcinoma | SWOG Cancer Research Network | Terminated | No outcome recorded |
| Phase 2 | NCT00002785 Background | Jul 1996 → Aug 2000 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002756 Background | Jun 1996 → Sep 2007 | leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 2 | NCT00002704 Background | Jan 1996 → Jun 2004 | leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00002865 Background | Apr 1995 → Jun 2000 | leukemia | Wake Forest University Health Sciences | Completed | No outcome recorded |
| Phase 2 | NCT00002552 Background | Oct 1993 → Sep 2001 | plasma cell neoplasm | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 2 | NCT00002494 Background | May 1992 → Mar 2004 | leukemia, lymphoma | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 2 | NCT00002471 Background | Feb 1990 → Jan 2003 | leukemia, lymphoma | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 2/36 trials | ||||||
| Phase 2/3 | NCT07072585 Background | Aug 2026 → Sep 2035 expected | T-cell acute lymphoblastic leukemia, T-lymphoblastic lymphoma | Children's Oncology Group | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT03371784 Comparator | Mar 2018 → Dec 2019 | ST-elevation myocardial infarction | Iuliu Hatieganu University of Medicine and Pharmacy | Unknown | No outcome recorded |
| Phase 2/3 | NCT02700828 Comparator | Feb 2016 → Nov 2017 | brain hypoxia - ischemia, perinatal asphyxia | Semmelweis University | Completed | No outcome recorded |
| Phase 2/3 | NCT02451774 Comparator | Jan 2015 → Dec 2019 | childhood acute lymphoblastic leukemia | Ramón Óscar González-Ramella, Ph.D | Unknown | No outcome recorded |
| Phase 2/3 | NCT00720109 Background | Jul 2008 → Dec 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), acute lymphoblastic leukemia | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2/3 | NCT00915343 Comparator | Aug 2007 → Jul 2008 | primary adrenal insufficiency | Shire | Completed | No outcome recorded |
| Phase 349 trials | ||||||
| Phase 3 | NCT07536399 Comparator | Apr 2026 → Dec 2027 expected | mouth disorder, temporomandibular joint disorder | Weill Medical College of Cornell University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06136624 Background | Dec 2023 → Aug 2028 expected | metastatic prostate carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT06136650 Background | Dec 2023 → May 2028 expected | castration-resistant prostate carcinoma | Merck Sharp & Dohme LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05894954 Background | Jul 2023 → Oct 2025 | cognitive impairment with or without cerebellar ataxia, dementia | Alzheimer's Prevention and Reversal Project, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT05063994 Comparator | May 2022 → Feb 2024 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine UK Limited | Completed | No outcome recorded |
| Phase 3 | NCT05139849 Comparator | Nov 2021 → Jan 2027 expected | post-cardiac arrest syndrome | Tiohundra AB | Recruiting | No outcome recorded |
| Phase 3 | NCT05192213 Background | Aug 2021 → Jul 2022 | infectious disease with sepsis | Hospital Sirio-Libanes | Terminated | No outcome recorded |
| Phase 3 | NCT06729593 Background | Apr 2021 → Aug 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT06729606 Background | Apr 2021 → Aug 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04843761 Background | Apr 2021 → Aug 2022 | COVID-19 | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 3 | NCT04293562 Background | Jul 2020 → Jun 2029 expected | acute myeloid leukemia | Children's Oncology Group | Recruiting | No outcome recorded |
| Phase 3 | NCT04381936 Comparator | Mar 2020 → Sep 2028 expected | pneumonia | University of Oxford | Recruiting | No outcome recorded |
| Phase 3 | NCT04301479 Comparator | Mar 2020 → Mar 2021 | vascular disorder | Instituto do Coracao | Unknown | No outcome recorded |
| Phase 3 | NCT04197115 Comparator | Sep 2019 → Aug 2020 | infectious disease with sepsis | IMSS Hospital General de Zona 11, Piedras Negras | Completed | No outcome recorded |
| Phase 3 | NCT04508946 Background | Aug 2019 → Nov 2020 | infectious disease with sepsis | Air Force Specialized Hospital, Cairo, Egypt | Completed | No outcome recorded |
| Phase 3 | NCT03401398 Comparator | Mar 2019 → Sep 2026 expected | infectious disease with sepsis | Jerry Zimmerman | Recruiting | No outcome recorded |
| Phase 3 | NCT03532022 Comparator | Oct 2018 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Neurocrine UK Limited | Withdrawn | No outcome recorded |
| Phase 3 | NCT03568318 Background | Aug 2018 → Feb 2021 overdue | atopic eczema | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03007147 Background | Aug 2017 → Sep 2027 expected | B-cell acute lymphoblastic leukemia, T-cell acute lymphoblastic leukemia, mixed phenotype acute leukemia | Children's Oncology Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03123718 Background | Jul 2017 → Jun 2021 | diffuse large B-cell lymphoma | Chonnam National University Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03020030 Background | Mar 2017 → Nov 2026 expected | childhood acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02473263 Comparator | May 2016 → Feb 2019 | — | Assistance Publique - Hôpitaux de Paris | Completed | No outcome recorded |
| Phase 3 | NCT02602210 Comparator | Jan 2015 → Dec 2020 | cirrhosis of liver | Universitaire Ziekenhuizen KU Leuven | Terminated | No outcome recorded |
| Phase 3 | NCT02101853 Background | Dec 2014 → Jun 2021 overdue | B-cell acute lymphoblastic leukemia | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02196142 Comparator | Nov 2014 → Jun 2015 | alcohol dependence | Insel Gruppe AG, University Hospital Bern | Completed | No outcome recorded |
| Phase 3 | NCT02112916 Background | Oct 2014 → Mar 2020 overdue | T-cell childhood acute lymphocytic leukemia, T-cell childhood lymphoblastic lymphoma | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 3 | NCT01954056 Comparator | Jun 2014 → Mar 2018 | vascular insufficiency disorder | NICHD Neonatal Research Network | Completed | No outcome recorded |
| Phase 3 | NCT02714543 Comparator | Nov 2013 → Aug 2015 | oral submucous fibrosis | The Oxford Dental College, Hospital and Research Center, Bangalore, India | Completed | No outcome recorded |
| Phase 3 | NCT01395966 Comparator | Jun 2011 → Jun 2014 | otitis media | Salvat | Completed | No outcome recorded |
| Phase 3 | NCT01007591 Comparator | Oct 2009 → Jun 2010 | psoriasis | LEO Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00694408 Comparator | Jun 2008 → Aug 2011 | — | Birmingham Women's and Children's NHS Foundation Trust | Terminated | No outcome recorded |
| Phase 3 | NCT00625209 Comparator | Mar 2008 → Jun 2015 | infectious disease with sepsis | University of Versailles | Completed | No outcome recorded |
| Phase 3 | NCT00557193 Background | Jan 2008 → Sep 2017 | T-cell childhood acute lymphocytic leukemia, acute undifferentiated leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00334672 Background | Mar 2006 → Nov 2010 | — | Children's Cancer and Leukaemia Group | Unknown | No outcome recorded |
| Phase 3 | NCT00320099 Background | Jan 2006 → Jan 2009 | infectious disease with sepsis | University of Versailles | Completed | No outcome recorded |
| Phase 3 | NCT00375713 Background | Oct 2005 → May 2006 | dermatitis | UCB Pharma | Completed | No outcome recorded |
| Phase 3 | NCT00400946 Background | Apr 2005 → Aug 2014 | leukemia, poisoning | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00002757 Comparator | Jun 2001 → Oct 2003 | leukemia, lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00165178 Background | Sep 2000 → Dec 2004 | childhood acute lymphoblastic leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00006455 Background | Nov 1999 → Jan 2009 | lymphoma | Gustave Roussy, Cancer Campus, Grand Paris | Completed | No outcome recorded |
| Phase 3 | NCT00003728 Background | Dec 1998 → May 2008 | leukemia, lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Unknown | No outcome recorded |
| Phase 3 | NCT00003215 Background | Apr 1997 → Mar 2004 | lymphoma | Swiss Cancer Institute | Completed | No outcome recorded |
| Phase 3 | NCT00002816 Background | Dec 1996 → Nov 2002 | acute leukemia | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002881 Background | Oct 1996 → Apr 1998 | prostate cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002855 Background | Aug 1996 → Jun 2005 | prostate cancer | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 3 | NCT00002798 Background | Aug 1996 → Sep 2006 | acute erythroid leukemia, acute monocytic leukemia, acute myeloblastic leukemia with maturation, acute myeloblastic leukemia without maturation +8 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 3 | NCT00002760 Comparator | Aug 1996 → Mar 2004 | prostate cancer | Alliance for Clinical Trials in Oncology | Completed | No outcome recorded |
| Phase 3 | NCT01230983 Background | Jun 1996 → Sep 2001 | acute leukemia, chemotherapy-induced toxicity, lymphoma | Children's Oncology Group | Completed | No outcome recorded |
| Phase 3 | NCT00002700 Background | Aug 1995 → Mar 2004 | acute leukemia, lymphoma | European Organisation for Research and Treatment of Cancer - EORTC | Completed | No outcome recorded |
| Phase 439 trials | ||||||
| Phase 4 | NCT07703098 Comparator | Sep 2026 → Sep 2029 expected | adrenocortical insufficiency | University Medical Centre Ljubljana | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07494084 Comparator | Jul 2026 → Mar 2029 expected | circadian rhythm sleep disorder, shift work type | Washington State University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06892197 Comparator | Mar 2026 → Aug 2030 expected | pneumonia | Copenhagen Respiratory Research | Recruiting | No outcome recorded |
| Phase 4 | NCT06892210 Comparator | Mar 2026 → Aug 2030 expected | chronic obstructive pulmonary disease | Copenhagen Respiratory Research | Recruiting | No outcome recorded |
| Phase 4 | NCT06982183 Comparator | May 2025 → Sep 2026 expected | acute stress disorder | Walter Reed Army Institute of Research (WRAIR) | Recruiting | No outcome recorded |
| Phase 4 | NCT06289673 Background | Dec 2024 → May 2034 expected | acute lymphoblastic leukemia, lymphoblastic lymphoma, mixed phenotype acute leukemia | St. Jude Children's Research Hospital | Recruiting | No outcome recorded |
| Phase 4 | NCT07154849 Comparator | Nov 2024 → Nov 2025 overdue | benign shuddering attacks | Ain Shams University | Recruiting | No outcome recorded |
| Phase 4 | NCT06122987 Background | Dec 2023 → Dec 2024 | infectious disease with sepsis | Kingman Regional Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT05435781 Comparator | Jun 2022 → Jun 2026 overdue | adrenocortical insufficiency, polymyalgia rheumatica, temporal arteritis | Marianne Christina Klose | Recruiting | No outcome recorded |
| Phase 4 | NCT05324618 Comparator | May → Nov 2022 | atopic eczema | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT05193396 Comparator | Feb 2022 → Jan 2026 overdue | adrenocortical insufficiency, polymyalgia rheumatica, temporal arteritis | Marianne Andersen | Recruiting | No outcome recorded |
| Phase 4 | NCT05836610 Comparator | Sep 2021 → Sep 2027 expected | brain hypoxia - ischemia, hypotensive disorder, perinatal asphyxia | Semmelweis University | Recruiting | No outcome recorded |
| Phase 4 | NCT03832010 Comparator | Dec 2019 → Feb 2024 | atopic eczema | Johns Hopkins University | Completed | No outcome recorded |
| Phase 4 | NCT04137302 Comparator | Nov 2019 → Jan 2020 | — | Centre Hospitalier Régional d'Orléans | Completed | No outcome recorded |
| Phase 4 | NCT04325490 Comparator | Oct 2019 → Sep 2020 | intertrigo | Mahidol University | Completed | No outcome recorded |
| Phase 4 | NCT04082533 Comparator | Jul 2019 → May 2026 overdue | osteoarthritis, knee | Hospital for Special Surgery, New York | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03910088 Comparator | Apr → Jun 2019 | intracranial hypotension | Cairo University | Completed | No outcome recorded |
| Phase 4 | NCT03635957 Background | Sep 2018 → Oct 2019 | gout | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT04492280 Comparator | Sep 2018 → Sep 2019 | infectious disease with sepsis | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT03585829 Comparator | May → Jun 2018 | pituitary deficiency | University Tunis El Manar | Completed | No outcome recorded |
| Phase 4 | NCT03282487 Comparator | Sep 2017 → Sep 2019 | adrenocortical insufficiency | The Adelaide and Meath Hospital, incorporating The National Children's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03110198 Comparator | May 2017 → Jan 2018 | ulcerative colitis | Xijing Hospital of Digestive Diseases | Unknown | No outcome recorded |
| Phase 4 | NCT02997605 Comparator | Jan 2017 → Jan 2022 | rheumatoid arthritis | University Hospital, Toulouse | Completed | No outcome recorded |
| Phase 4 | NCT02425852 Comparator | Dec 2016 → Jun 2022 | ulcerative colitis | Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives | Completed | No outcome recorded |
| Phase 4 | NCT02760862 Comparator | Oct 2014 → Nov 2015 | headache disorder | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02277587 Comparator | Mar 2014 → Jun 2016 | primary adrenal insufficiency, secondary adrenal insufficiency | University of Roma La Sapienza | Completed | No outcome recorded |
| Phase 4 | NCT01941589 Comparator | Sep 2013 → Apr 2021 | ulcerative colitis | Sheba Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT02190994 Comparator | Aug 2013 → Aug 2014 | craniopharyngioma, pituitary tumor | West China Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01448109 Comparator | Jun 2012 → Oct 2017 | infectious disease with sepsis | The George Institute | Completed | No outcome recorded |
| Phase 4 | NCT01546922 Comparator | Feb 2012 → Jun 2013 | secondary adrenal insufficiency | University Medical Center Groningen | Completed | No outcome recorded |
| Phase 4 | NCT01815918 Comparator | Feb 2011 → Apr 2012 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| Phase 4 | NCT01095172 Background | Nov 2010 → Oct 2020 | — | Guy's and St Thomas' NHS Foundation Trust | Unknown | No outcome recorded |
| Phase 4 | NCT01089075 Comparator | Feb 2010 → Mar 2015 | pituitary deficiency | Max-Planck-Institute of Psychiatry | Terminated | No outcome recorded |
| Phase 4 | NCT00773058 Comparator | Dec 2008 → Apr 2009 | acute respiratory distress syndrome, adrenocortical insufficiency | Southeast University, China | Unknown | No outcome recorded |
| Phase 4 | NCT00490828 Comparator | Jun 2007 → May 2008 | autoinflammatory syndrome, post-traumatic stress disorder | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT00842933 Comparator | May 2007 → May 2010 | acute adrenal insufficiency, infectious disease with sepsis | The Methodist Hospital Research Institute | Terminated | No outcome recorded |
| Phase 4 | NCT00466258 Background | Oct 2006 → May 2009 | HIV infectious disease, diffuse large B-cell lymphoma | PETHEMA Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00368381 Comparator | Sep 2006 → Jul 2009 | adrenocortical insufficiency, infectious disease with sepsis | CAMC Health System | Withdrawn | No outcome recorded |
| Phase 4 | NCT01091337 Background | May 2006 → Sep 2009 | asthma | Otsuka Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase not applicable30 trials | ||||||
| — | NCT07558135 Comparator | Sep 2026 → Sep 2028 expected | adrenal gland disorder | King's College Hospital NHS Trust | Not yet recruiting | No outcome recorded |
| — | NCT05716607 Comparator | Jan 2025 → Jul 2026 | autoimmune polyendocrinopathy, diabetes mellitus, primary adrenal insufficiency | Vastra Gotaland Region | Withdrawn | No outcome recorded |
| — | NCT06723626 Comparator | Jul 2024 → Nov 2025 overdue | infectious disease with sepsis | Southeast University, China | Recruiting | No outcome recorded |
| — | NCT06930456 Comparator | Mar 2024 → Mar 2025 overdue | hypotensive disorder | Nada kamel Elgamal | Enrolling by invitation | No outcome recorded |
| — | NCT06576245 Background | Sep 2023 → Feb 2024 | dry eye syndrome | University of Seville | Completed | No outcome recorded |
| — | NCT05354778 Comparator | Oct 2022 → Dec 2026 expected | nosocomial infection | Instituto de Assistencia Medica ao Servidor Publico Estadual, Sao Paulo | Recruiting | No outcome recorded |
| — | NCT05710068 Background | Dec 2021 → Aug 2022 | hyperpigmentation of the skin | Ajou University School of Medicine | Completed | No outcome recorded |
| — | NCT04621565 Comparator | Nov 2020 → Jul 2022 | adrenocortical insufficiency, pituitary gland adenoma | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT04359147 Comparator | Nov 2019 → Dec 2021 | — | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT03821714 Comparator | Feb 2019 → Jan 2020 | infectious disease with sepsis | Southeast University, China | Completed | No outcome recorded |
| — | NCT03649009 Comparator | Jan → Dec 2018 | lactic acidosis | Universiti Kebangsaan Malaysia Medical Centre | Unknown | No outcome recorded |
| — | NCT03465007 Comparator | Oct 2017 → Jul 2018 | acute hypotension | University of Jordan | Completed | No outcome recorded |
| — | NCT03258684 Comparator | Sep 2017 → Feb 2019 | infectious disease with sepsis | Zhujiang Hospital | Completed | No outcome recorded |
| — | NCT02289989 Comparator | Nov 2014 → Jan 2017 | atopic eczema | Rutgers, The State University of New Jersey | Terminated | No outcome recorded |
| — | NCT02112019 Comparator | Jun 2014 → Dec 2017 | Sjogren syndrome | Derk Jan Jager | Unknown | No outcome recorded |
| — | NCT02152553 Comparator | May 2014 → Dec 2016 | primary adrenal insufficiency | Vastra Gotaland Region | Completed | No outcome recorded |
| — | NCT02523664 Comparator | Jan 2014 → Dec 2018 | borderline personality disorder, post-traumatic stress disorder | Charite University, Berlin, Germany | Completed | No outcome recorded |
| — | NCT01691209 Comparator | Oct 2013 → Apr 2014 | atopic eczema | Bayer | Withdrawn | No outcome recorded |
| — | NCT01782859 Comparator | Oct 2012 → Jan 2014 | — | Hospital for Special Surgery, New York | Completed | No outcome recorded |
| — | NCT02084134 Comparator | Mar 2012 → Nov 2016 | pituitary gland adenoma | Washington University School of Medicine | Completed | No outcome recorded |
| — | NCT01284452 Comparator | Dec 2010 → Dec 2014 | acute lung injury, acute respiratory distress syndrome, infectious disease with sepsis | Mahidol University | Completed | No outcome recorded |
| — | NCT01559675 Comparator | Sep 2010 → Apr 2012 | orthostatic hypotension | Cedars-Sinai Medical Center | Completed | No outcome recorded |
| — | NCT01090518 Comparator | Feb 2010 → Nov 2013 | post-traumatic stress disorder | Bronx VA Medical Center | Unknown | No outcome recorded |
| — | NCT01074567 Background | Dec 2009 → Dec 2011 | interstitial cystitis | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| — | NCT00751855 Comparator | Jul 2008 → Feb 2011 | post-traumatic stress disorder | VISN 3 Mental Illness Research, Education and Clinical Center | Completed | No outcome recorded |
| — | NCT00675272 Comparator | May 2008 → Aug 2011 | — | Kuopio University Hospital | Terminated | No outcome recorded |
| — | NCT00550992 Background | Jan 2006 → Dec 2020 | leukemia | Dutch Childhood Oncology Group | Unknown | No outcome recorded |
| — | NCT00597857 Comparator | Jun 2005 → Aug 2009 | post-traumatic stress disorder | Kent State University | Unknown | No outcome recorded |
| — | NCT00688987 Comparator | Aug 2000 → Jul 2004 | obesity disorder, primary adrenal insufficiency | Oregon Health and Science University | Completed | No outcome recorded |
| — | NCT01228110 Comparator | — | — | Cairo University | Completed | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04456439 Background | — | COVID-19–associated multisystem inflammatory syndrome in children | Mesoblast, Ltd. | No longer available | No outcome recorded |
| — | NCT05974410 Background | — | Hodgkins lymphoma, brain neoplasm, breast cancer, desmoplastic small round cell tumor +10 | AVM Biotechnology Inc | Available | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2021-02-10 | Gilead Sciences | Kite Announces New ZUMA-1 Cohort Analysis Evaluating Prophylactic Corticosteroid Use With Yescarta® in Patients With Relapsed or Refractory Large B-cell lymphoma gilead.com ↗ |
| 2020-12-22 | Amgen | Update On SOURCE Phase 3 Trial For Tezepelumab In Patients With Severe, Oral Corticosteroid-Dependent Asthma amgen.com ↗ |
Evidence & citations 36 cited values
Every value below carries the sentence it was read from. 476 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hydrocortisone | “Patients were randomized to receive either preservative-free hydrocortisone 0.335% (Softacort, Laboratories Thea, France) for 12 days four times daily followed by 2 days twice...” PMID 31741283 ↗ Nov 2019413“Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher,...” NCT00332163 ↗ “Patients were randomly assigned in a 1:1 ratio to either replace prednisone with 20 mg/day of hydrocortisone for 3 months, then reduce to 10 mg/day for 3 months before...” PMID 39874233 ↗ Jan 2025 “Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with...” NCT03123718 ↗ “Intrathecal chemotherapy will consist of either single-agent cytarabine or methotrexate, or a combination of methotrexate, cytarabine, and hydrocortisone, at appropriate...” NCT04029688 ↗ “Recommended TCS include triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment as medium potency topical corticosteroids and hydrocortisone 1% cream as...” NCT03568318 ↗ “Patients received bisoprolol as group (A) in addition hydrocortisone 100 mg intravenously is given in the evening of the operation and then 100 mg every eight hours during the...” NCT03800264 ↗ “Agents for intrathecal (IT) chemotherapy, central nervous system (CNS)-1/2: IT methotrexate chemotherapy, or CNS-3: triple intrathecal (ITT) methotrexate, hydrocortisone, cytarabine.” NCT04501614 ↗ “This first ever study in patients with CAH is a pharmacokinetic/pharmacodynamic study comparing Chronocort to Cortef, the conventional immediate-release form of hydrocortisone.” NCT00519818 ↗ “hydrocortisone 1% cream (HCT) was applied twice daily for 4 weeks on one side of forehead skin without clinical signs of AD and pimecrolimus 1% cream (PIM) on the other.” PMID 21771098 ↗ Jul 2011 “Treatment A is 10 mg hydrocortisone (2 tablets Cortef, 5 mg each),Stress-dose will be taken per os one time 2 tablets 10 mg of Cortef 60 min before start of exercise.” NCT01847690 ↗ “Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.” NCT02716818 ↗ “Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).” NCT00298155 ↗ “Methotrexate, hydrocortisone and cytarabine are combined into one preparation for intrathecal administration at multiple time points during treatment.” NCT07059975 ↗ “Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.” NCT02671058 ↗ “Atrophic subtype support may include: estradiol, progesterone, testosterone, DHEA, pregnenolone, levothyroxine, liothyronine, hydrocortisone.” NCT05894954 ↗ “receiving intravenous Vitamin C (1.5 g every 6 hours), Thiamine (200 mg every 12 hours) and Hydrocortisone (50 mg every 6 hours) for 7 days” NCT05192213 ↗ “Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).” NCT02733367 ↗ “In each stratum, patients will be randomly assigned to receive a 7-day course of hydrocortisone and fludrocortisone or their placebos.” PMID 36898751 ↗ Mar 2023 “Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS 3 at study entry.” NCT00928200 ↗ “ME-609 (Xerese, Xerclear) is a combination of 5% acyclovir and 1% hydrocortisone developed for the topical treatment of HSL.” PMID 20851499 ↗ Sep 2010 “Chronocort (hydrocortisone modified-release hard capsule) supplied as 5 mg and 10 mg strengths will be administered orally.” NCT05222152 ↗ “Hydrocortisone：For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days” NCT05658692 ↗ “In the last week of treatment, subjects will receive 90 mg/day of oral hydrocortisone or a placebo for 4 consecutive days.” NCT00220454 ↗ “Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19” NCT02451774 ↗ “Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.” NCT06979596 ↗ “Other forms of corticosteroids are also acceptable e.g. hydrocortisone, methylprednisolone at the equivalent dosage.” NCT06446245 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT04843761 ↗ “intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%” NCT01074567 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729593 ↗ “corticosteroids such as dexamethasone, prednisone, methylprednisolone or hydrocortisone may be administered as SOC.” NCT06729606 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05745714 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT07175415 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05658640 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05751044 ↗ “IT: Methotrexate +/- prednisone/hydrocortisone/cytarabine according to the degree of central nervous involvement” NCT05740449 ↗ “Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.” NCT02922374 ↗ “Patients in Arm 1 will randomized to receive usual care + hydrocortisone, thiamine and ascorbic acid.” NCT04134403 ↗ “Patients will be randomized to receive either hydrocortisone 50 mg IV every six hours for seven days” NCT00842933 ↗ “replacing the intrathecal methotrexate to intrathecal cytarabine, methotrexate and hydrocortisone.” NCT02339350 ↗ “triple intrathecal therapy (TIT) (Methotrexate [MTX]: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg).” NCT02776605 ↗ “hydrocortisone, ascorbic acid (vitamin C), and thiamine (vitamin B1); referred to as HAT” NCT05157360 ↗ “Hydrocortisone (dose range 10 to 30) mg will be continued as before entering the study.” NCT02277587 ↗ “An 8 ml of hydrocortisone will be injected in the ME through posteroinferior part of TM” NCT05112354 ↗ “hydrocortisone (200 mg IV) will be administered immediately prior to each infusion.” NCT03635957 ↗ “Over-encapsulated hydrocortisone modified-release capsule for oral administration.” NCT05063994 ↗ “TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily” NCT02340234 ↗ “5% hydroquinone, 0.003% tretinoin, and 1% hydrocortisone twice daily for 2 months” NCT05710068 ↗ “Hydrocortisone hemisuccinate 50 mg: one intravenous injection every 6 hours” NCT04404400 ↗ “Immediate release multiparticulate formulation (granules) of hydrocortisone” NCT03311932 ↗ “single dose of 20mg modified release hydrocortisone in the absence of food” NCT02408068 ↗ “Hydrocortisone, 100 mg IV shall be given immediately at start of treatment” NCT01091337 ↗ “Hydrocortisone intravenous: 100mg hydrocortisone as sodium succinate i.v.” NCT07262957 ↗ “IT cytarabine, methotrexate, and either prednisolone or hydrocortisone” NCT03793478 ↗ “Oral administration of Hydrocortisone will increase HPA axis activity.” NCT02372110 ↗ “Methotrexate 12 mg IT, Hydrocortisone 24mg IT, Cytarabine 36mg IT” NCT05192889 ↗ “Immediate-release multiparticulate formulation of hydrocortisone.” NCT03178214 ↗ “methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)” NCT00466258 ↗ “Hydrocortisone modified release capsules - 5mg, 10mg and 20mg.” NCT03532022 ↗ “Postoperative administration of hydrocortisone for one month” NCT07558811 ↗ “Idroflog® (0.2% Hyaluronic Acid with 0.001% Hydrocortisone)” NCT06576245 ↗ “100mg of Hydrocortisone will be injected In the peritoneum” NCT03845608 ↗ “Yohimbine hydrochloride 60mg + Hydrocortisone 20mg tablet” NCT03015246 ↗ “Hydrocortisone 200mg continuous intravenous infusion(24h)” NCT03821714 ↗ “conventional GCs (cortisone acetate or hydrocortisone)” PMID 39171906 ↗ Aug 2024 “Hydrocortisone modified-release capsule 5 mg and 10 mg” NCT05299554 ↗ “Cortef® Immediate Release Hydrocortisone Tablets” NCT03343327 ↗ “once-daily, modified-release oral hydrocortisone” PMID 29229498 ↗ Dec 2017 “Perioperative Hydrocortisone Reduction Therapy” NCT06679816 ↗ “intravenous hydrocortisone 80 mg twice daily” NCT04381936 ↗ “ME-609 (5% acyclovir and 1% hydrocortisone)” NCT00735761 ↗ “dry granule formulation of hydrocortisone” NCT02720952 ↗ “methotrexate/hydrocortisone/cytarabine” NCT02676323 ↗ “Methotrexate/hydrocortisone/cytarabine” NCT02553460 ↗ “Methotrexate/hydrocortisone/cytarabine” NCT02433483 ↗ “methotrexate/hydrocortisone/cytarabine” NCT05656248 ↗ “methotrexate/hydrocortisone/cytarabine” NCT06177067 ↗ “Hydrocortisone, Vitamin C and Thiamine” NCT03380507 ↗ “methotrexate/hydrocortisone/cytarabine” NCT03515200 ↗ “Methotrexate/Hydrocortisone/Cytarabine” NCT03164057 ↗ “methotrexate/hydrocortisone/cytarabine” NCT03194932 ↗ “Modified formulation of hydrocortisone” NCT03051893 ↗ “20 mg of Depomedrol (hydrocortisone)” NCT02417987 ↗ “Physical cooling,Hydrocortisone” NCT01973855 ↗ “* hydrocortisone 2.5%” NCT01313221 ↗ “Hydrocortisone cream” NCT00980135 ↗ “A: hydrocortisone” NCT02552251 ↗ “Hydrocortisone:” NCT00440726 ↗ “Hydrocortisone” NCT02716818 ↗ “hydrocortisone” NCT01941589 ↗ |
| Known as | 17-Hydroxycorticosterone | “Hydrocortisone (17-Hydroxycorticosterone) is the preferred cortisol replacement.” NCT06435481 ↗ |
| Known as | Chronocort | “Chronocort (hydrocortisone modified-release hard gelatin capsules for oral administration - 5mg and 10mg” NCT05222152 ↗1“Chronocort® modified release hydrocortisone” NCT03062280 ↗ |
| Known as | Cortef | “This was a two-part, single centre, open-label, randomised, single dose, two-period, crossover study to evaluate the bioavailability of Infacort® versus Cortef® immediate...” NCT03311932 ↗4“Hydrocortisone (Cortef™) 20mg tablet administered on one day.” NCT03015246 ↗ “Cortef (hydrocortisone)” NCT01063569 ↗ |
| Known as | Cortenema | “Hydrocortisone retention enema (Cortenema) administered rectally as a single dose; each dose unit delivers 100 mg of hydrocortisone per 60 mL.” NCT02671058 ↗ |
| Known as | Corticosteroid | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07536399 ↗ |
| Known as | cortisol | “This study will examine the effects of cortisol (hydrocortisone), melatonin, a combination of cortisol and melatonin, and placebo (an inactive substance) on jet lag symptoms.” NCT00097474 ↗9“Hydrocortisone is the pharmaceutical term for cortisol, the principal glucocorticoid secreted by the adrenal gland” NCT02700828 ↗ “intravenous hydrocortisone (cortisol) challenge” NCT03302416 ↗ |
| Known as | CORTIVIS | “Hydrocortisone (CORTIVIS ®)” NCT04536129 ↗ |
| Known as | DF277 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01395966 ↗ |
| Known as | HCT | “hydrocortisone 1% cream (HCT) was applied twice daily for 4 weeks on one side of forehead skin without clinical signs of AD and pimecrolimus 1% cream (PIM) on the other.” PMID 21771098 ↗ Jul 2011 |
| Known as | High Volume injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02417987 ↗ |
| Known as | Hy-Cortisone Injection | “single dose Hy-Cortisone Injection 250 mg (Generic name: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals Pakistan) intramuscularly after extraction” NCT06637384 ↗ |
| Known as | Hydrocortison | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01691209 ↗ |
| Known as | hydrocortisone acetate | “This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w).” NCT02301052 ↗9“Hydrocortisone or hydrocortisone/hydrocortisone acetate administered via intramuscular injection as rescue medication.” NCT06979596 ↗ “Anucort HC TM (Hydrocortisone Acetate) 25mg Rectal Suppositories” NCT01913158 ↗ |
| Known as | Hydrocortisone hemisuccinate | “Hydrocortisone hemisuccinate (Hydrocortisone Upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent.” NCT02768740 ↗3“HYDROCORTISONE HEMISUCCINATE Vials with lyophilisate (100mg hydrocortisone) are provided by SERB laboratory.” NCT04591990 ↗ “Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs” NCT02114710 ↗ “Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs” NCT02266589 ↗ |
| Known as | Hydrocortisone immediate release tablet | “Hydrocortisone immediate release tablet” NCT00519818 ↗ |
| Known as | Hydrocortisone modified-release hard capsule | “Hydrocortisone modified-release hard capsule” NCT05299554 ↗ |
| Known as | Hydrocortisone sodium acetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00529841 ↗ |
| Known as | Hydrocortisone Sodium Succinate | “The Children's Cancer Group (CCG) 1952 clinical trial for children with standard-risk acute lymphoblastic leukemia (SR-ALL) compared intrathecal (IT) methotrexate (MTX) with IT...” PMID 16609069 ↗ Apr 200617“Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the...” NCT01353313 ↗ “hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol)” NCT01954056 ↗ “Generic name: Hydrocortisone Sodium Succinate, Cirin Pharmaceuticals Pakistan” NCT06637384 ↗ “* Hydrocortisone sodium succinate (Solucortef) 100 mg” NCT00317070 ↗ “Drug: Hydrocortisone Sodium Succinate” NCT05761171 ↗ |
| Known as | Hydrocortisone Upjohn | “Hydrocortisone hemisuccinate (Hydrocortisone Upjohn) was supplied as a powder in 100 mg vials to be reconstituted with 2 ml of sterile water diluent.” NCT02768740 ↗ |
| Known as | Hydrocortisone-21-acetate | “Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.” NCT01055249 ↗ |
| Known as | Infacort | “This was a two-part, single centre, open-label, randomised, single dose, two-period, crossover study to evaluate the bioavailability of Infacort® versus Cortef® immediate...” NCT03311932 ↗2“Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0mg).” NCT02720952 ↗ “Infacort® is a dry granule formulation of hydrocortisone stored in capsules available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).” NCT02733367 ↗ |
| Known as | Intrathecal Triples | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02518750 ↗ |
| Known as | LDH | “low dose hydrocortisone (LDH)” NCT03237689 ↗ |
| Known as | MR-HC | “modified-release hydrocortisone (MR-HC), which mimics physiologic cortisol secretion” PMID 33527139 ↗ Apr 2021 |
| Known as | NSC-10483 | “Antiandrogen stopped; plus Ketoconazole, KCZ; Hydrocortisone, HC, NSC-10483.” NCT00002760 ↗ |
| Known as | Plenadren | “Thereafter participants are shifted to modified release hydrocortisone (Plenadren) once daily (OD), on a dose as per Summary of Product Characteristics (SmPC).” NCT02282150 ↗3“Plenadren (modified release hydrocortison) 20-25 or 30 mg oral tablets will be administered once-daily at 8.00 AM in the fasting state” NCT02277587 ↗ “Plenadren (hydrocortisone modified-release tablets for oral administration - 5mg and 20mg” NCT05222152 ↗ “Dual release hydrocortisone (plenadren)” NCT03760835 ↗ |
| Known as | Softacort | “Patients were randomized to receive either preservative-free hydrocortisone 0.335% (Softacort, Laboratories Thea, France) for 12 days four times daily followed by 2 days twice...” PMID 31741283 ↗ Nov 2019 |
| Known as | Solu-Cortef plain | “Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the...” NCT01353313 ↗ |
| Known as | SOLU-CORTEF- hydrocortisone sodium succinate injection | “SOLU-CORTEF- hydrocortisone sodium succinate injection” NCT03401398 ↗ |
| Known as | Solucortef | “These patients will receive standard therapy for sepsis plus Hydrocortisone (Solucortef®, E.I.P.I.co. under license of Pfizer) at dose 50mg every 6 hours by Intra venous route.” NCT04492280 ↗6“treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable” NCT01423864 ↗ “* Hydrocortisone sodium succinate (Solucortef) 100 mg” NCT00317070 ↗ “Hydrocortisone Injection (also known as solu-cortef)” NCT04037605 ↗ “Hydrocortisone (Solucortef)” NCT01859312 ↗ |
| Known as | Solucortif | “hydrocortisone (Solucortif® 100 mg , vial, dried powder Pfizer, Egypt) 50 mg diluted in 5 ml normal saline IV / 6 h” NCT04160676 ↗ |
| Known as | therapeutic hydrocortisone | “Drug: therapeutic hydrocortisone” NCT00006371 ↗ |
| Action | Restore | “Glucocorticoid needed to replace cortisol deficiency.” NCT00001521 ↗ |
| Modality | Other / unclassified | “intravenous corticosteroid administration after cardiac surgery” NCT00442494 ↗ |
| Route | Oral | “low-dose hydrocortisone (6-8 mg/m\^2/day orally)” NCT00001521 ↗ |